Why I am writing about menopause and lipedema now

A 2025 review suggests menopause may be a turning point in lipedema, as hormone signalling in fat tissue can shift and fuel pain, swelling, and fibrosis.

I am not in menopause yet. Still, it is a life stage I know is ahead, and it matters to me to understand what might change when hormones shift. I also care about sharing that knowledge with you, especially those of you who are already in perimenopause or menopause and living with lipedema right now.

This post covers a narrative review published in July 2025 in the International Journal of Molecular Sciences. The authors argue that menopause can be a turning point in lipedema progression. I want you to understand what they propose, why it is biologically plausible, and where the evidence is still thin. I also want to invite you into 2026 with me as an active participant in learning and in pushing lipedema knowledge forward. Many researchers and clinical professionals read my writing. Your lived experience can generate better hypotheses for them to test. If something resonates, please share it.

What the paper is and what it is not

The paper is a narrative review. That means it does not present a new clinical trial or a new dataset. It builds a model by connecting findings from different areas such as adipose tissue biology, menopause research, and estrogen driven gynecological conditions. The authors are explicit about a major limitation. Lipedema specific randomized trials are missing, so several treatment ideas remain theory plus extrapolation.